Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 18/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18226830 | 0.90 | GABRG2 (0.41) | CDK9CYP11B2 | |
| SCHEMBL30963003 | 0.80 | BRD4 (0.41) | CDK9CYP11B2BRD4BAZ2A | |
| SCHEMBL30960753 | 0.76 | FGFR1 (0.36) | CDK9 | |
| SCHEMBL2195860 | 0.73 | YTHDC1 (0.54) | CYP11B2BRD4BAZ2A | |
| SCHEMBL30960701 | 0.73 | PDE5A (0.39) | BRD4BAZ2A | |
| SCHEMBL30960694 | 0.73 | PDE5A (0.38) | BRD4BAZ2A | |
| SCHEMBL29480813 | 0.73 | CYP11B2 (0.42) | CDK9CYP11B2 | |
| SCHEMBL2198112 | 0.71 | PDE8A (0.60) | — | |
| SCHEMBL16034860 | 0.70 | CDK9 (0.48) | CDK9 | |
| SCHEMBL27453692 | 0.70 | HSD17B13 (0.42) | CDK9CYP11B2BRD4BAZ2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646411-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024148089-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| US-9650358-B2 | Pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2970268-A1 | CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970200-A1 | PYRIDINE CDK9 KINASE INHIBITORS | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-8969375-B2 | CDK9 kinase inhibitors | ABBVIE, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| WO-2014160017-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014159999-A1 | CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275153-A1 | CDK9 KINASE INHIBITORS | ABBIVE INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK6 | CDK9 1/4885CYP11B2 2285/4885BRD4 332/4885 |
| US-20140275153-A1 | CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK10 | CDK9 1/4885CYP11B2 3569/4885BRD4 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.